Which manufacturer produces Enasidenib?

Enasidenib is an original drug produced by Celgene Corporation. Celgene is a world-renowned biopharmaceutical company that was later acquired by Bristol-Myers Squibb (BMS) and became its subsidiary. Celgene has a long-standing commitment to developing innovative therapeutics, particularly in the fields of cancer and immunology. Ensidipine is an important targeted drug developed by the company. It is mainly used to treat acute myeloid leukemia (AML), especially for patients with IDH2 mutations.

The development of ensidipine marks a major breakthrough in targeted therapy drugs in the treatment of hematological diseases. By precisely targeting IDH2 gene mutations, ensidipine can effectively intervene in the occurrence and development of AML and help patients restore normal blood cell functions. Celgene leverages its technical advantages in the field of molecularly targeted drugs to bring this innovative drug to the market and provide new treatment options for AML patients around the world.

With the acquisition of Celgene by Bristol-Myers Squibb (BMS), the production, sales and promotion of ensidipine have been transferred to BMS. BMS has a strong marketing network and sales channels around the world, allowing Ensidipine to enter more countries and regions and benefit more patients. The launch of this drug not only provides a new treatment option for AML patients, but also further promotes the application of targeted therapy drugs in cancer treatment.

Celgene (now BMS) has always focused on developing and producing innovative drugs. As one of its core products, ensidipine is not only technically advanced, but also recognized by many patients and doctors for its therapeutic effect. As the global demand for precision medicine and personalized treatment continues to increase, ensidipine will continue to play an important role in the treatment of AML.

Reference materials:https://www.idhifa.com/